边缘区淋巴瘤的诊断与治疗进展

罗丽卿; 彭振翼; 王涛

doi:10.12122/j.issn.1674-4500.2019.03.19

边缘区淋巴瘤的诊断与治疗进展

doi: 10.12122/j.issn.1674-4500.2019.03.19

罗丽卿^1,,
彭振翼²,
王涛^3, ,

1.
滨州医学院附属医院血液科
2.
滨州医学院附属医院甲乳外科
3.
滨州医学院附属医院检验科，山东滨州 256603

基金项目: 山东省自然科学基金（ZR2017PH014）

详细信息

作者简介:
罗丽卿，硕士，检验医师，E-mail：luoliqingwutai@163.com

通讯作者:
王涛，硕士，主管技师，E-mail：wangtaoliwang@163.com

计量
- 文章访问数: 1811
- HTML全文浏览量: 500
- PDF下载量: 55
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-15
- 刊出日期: 2019-07-01

Diagnosis and treatment advance of marginal zone lymphoma

Liqing LUO^1
,,
Zhenyi PENG²,
Tao WANG^{3
, ,}

1.
Department of Hematology
2.
Department of Thyroid and Breast Surgery
3.
Department of Clinical Laboratory, Binzhou Medical University Hospital, Binzhou 256603, China

摘要

摘要: 边缘区淋巴瘤是起源于边缘区记忆淋巴细胞的惰性肿瘤，属于小B细胞淋巴瘤。边缘区淋巴瘤分为脾边缘区淋巴瘤、黏膜相关淋巴组织淋巴瘤和淋巴结边缘区淋巴瘤。它们有各自不同的临床特征、形态学和病理学特征、免疫表型特征及分子遗传学特征，对其综合分析有助于各型边缘区淋巴瘤的诊断，以及与其他小B细胞淋巴瘤的鉴别诊断。近年来，随着对边缘区淋巴瘤发病机制的研究不断深入，临床治疗不断进展，许多新药物逐渐应用到临床试验中，为边缘区淋巴瘤患者的治疗提供新的希望。
- 边缘区淋巴瘤 /
- 诊断 /
- 鉴别诊断 /
- 治疗
Abstract: The marginal zone lymphoma (MZL) is an invasive tumor originating from the memory cells in the marginal zone and belongs to small B-cell lymphoma. MZL is divided into spleen marginal zone lymphoma (SMZL), mucosa-associated lymphoid tissue (MALT) lymphoma,and lymph node marginal zone lymphoma (NMZL). They have different clinical characteristics, morphological and pathological features, immunophenotypic characteristics and molecular genetic characteristics. Comprehensive analysis is helpful for the diagnosis of marginal lymphoma subtypes and differential diagnosis with other small B cell lymphomas.In recent years, with further study of the pathogenesis of MZL, clinical treatment has been progressing, and many new drugs have been used in clinical trails, promising new hope for MZL patients.
- Marginal Zone Lymphoma /
- diagnosis /
- differentiation /
- treatment

HTML全文

参考文献(43)

[1]	Swerdlow SH, Harris NL, Pileri S, et al. 造血与淋巴组织肿瘤WHO分类(第四版上册+下册)[M].北京: 诊断病理学杂志社, 2011.
[2]	徐卫. 小B细胞淋巴瘤的诊断[J]. 临床内科杂志, 2015, 32(3): 163-5. doi: 10.3969/j.issn.1001-9057.2015.03.07
[3]	楚松林, 彭敏敏, 张连生. 脾边缘带淋巴瘤诊治新进展[J]. 中华血液学杂志, 2014, 35(11): 1034-7. doi: 10.3760/cma.j.issn.0253-2727.2014.11.021
[4]	Piris MA, Onaindia A, Mollejo M. Splenic marginal zone lymphoma[J]. Best Pract Res Clin Haematol, 2017, 30(1/2): 56-64.
[5]	孙琦, 张培红, 刘恩彬, 等. 脾脏B细胞边缘区淋巴瘤侵犯骨髓的病理学特点与鉴别诊断[J]. 中华病理学杂志, 2013, 42(4): 234-8. doi: 10.3760/cma.j.issn.0529-5807.2013.04.005
[6]	时云飞, 李向红. 滤泡树突细胞及Ki-67分布方式在小B细胞淋巴瘤鉴别诊断中的意义[J]. 中华病理学杂志, 2013, 42(4): 222-6. doi: 10.3760/cma.j.issn.0529-5807.2013.04.003
[7]	李增军, 邱录贵. 边缘区淋巴瘤的多面世界和研究进展: 从2012年美国血液学会年会报道说起[J]. 白血病·淋巴瘤, 2013, 22(1): 9-10. doi: 10.3760/cma.j.issn.1009-9921.2013.01.004
[8]	Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management[J]. Blood, 2016, 127(17): 2072-81. doi: 10.1182/blood-2015-11-624312
[9]	Moody S, Escudero-Ibarz L, Wang M, et al. Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma[J]. J Pathol, 2017, 243(1): 3-8. doi: 10.1002/path.2017.243.issue-1
[10]	Mendes L, Du MQ, Matutes E, et al. Splenic marginal zone lymphoma: a review of the clinical presentation, pathology, molecular biology, and management[J]. Blood Lymphat Cancer, 2014, 4(7): 29-38.
[11]	Thieblemont C, Davi F, Noguera ME, et al. Splenic marginal zone lymphoma: current knowledge and future directions[J]. Oncology (Williston Park), 2012, 26(2): 194-202.
[12]	Lenglet J, Traullé C, Mounier N, et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment[J]. Leuk Lymphoma, 2014, 55(8): 1854-60. doi: 10.3109/10428194.2013.861067
[13]	Olszewski AJ. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma[J]. Am J Hematol, 2012, 87(11): E119-22. doi: 10.1002/ajh.v87.11
[14]	Xing KH, Kahlon A, Skinnider BF, et al. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia[J]. Br J Haematol, 2015, 169(4): 520-7. doi: 10.1111/bjh.13320
[15]	Ayyappan S, William BM. Marginal Zone lymphoma: clinicopathologic variations and approaches to therapy[J]. Curr Oncol Rep, 2018, 20(4): 33-45. doi: 10.1007/s11912-018-0687-9
[16]	Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or withoutchemotherapy or chemotherapy alone[J]. Cancer, 2006, 107(1): 125-35. doi: 10.1002/(ISSN)1097-0142
[17]	Else M, Marin-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma[J]. Br J Haematol, 2012, 159(3): 322-8. doi: 10.1111/bjh.12036
[18]	Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy[J]. Oncologist, 2013, 18(2): 190-7. doi: 10.1634/theoncologist.2012-0251
[19]	Olszewski AJ, Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma[J]. Ann Hematol, 2014, 93(3): 449-58. doi: 10.1007/s00277-013-1900-4
[20]	Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma[J]. Hematol Oncol, 2007, 25(3): 127-31.
[21]	Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: consortium for improving survival of Lymphoma (CISL) study[J]. Ann Hematol, 2012, 91(4): 543-51. doi: 10.1007/s00277-011-1337-6
[22]	Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas[J]. Br J Haematol, 2009, 145(6): 741-8. doi: 10.1111/bjh.2009.145.issue-6
[23]	Ferrario A, Pulsoni A, Olivero B, et al. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation[J]. Cancer, 2012, 118(16): 3954-61. doi: 10.1002/cncr.26708
[24]	Zucca E, Conconi A, Martinelli G, et al. Final results of the IELSG-19 randomized trial of Mucosa-Associated lymphoid tissue lymphoma: improved Event-Free and Progression-Free survival with rituximab plus chlorambucil versus either chlorambucil or RituximabMonotherapy[J]. J Clin Oncol, 2017, 35(17): 1905-12. doi: 10.1200/JCO.2016.70.6994
[25]	Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial[J]. Lancet, 2013, 381(9873): 1203-10. doi: 10.1016/S0140-6736(12)61763-2
[26]	Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study[J]. Blood, 2014, 123(19): 2944-52. doi: 10.1182/blood-2013-11-531327
[27]	Salar A, Domingo-Domenech E, Panizo C, et al. Long-term results of the multicenter phase IItrial with Bendamustine and rituximab as first line treatment for patients with maltlymphoma (MALT-2008-01)[J]. Hematol Oncol, 2017, 35(S2): 147-8.
[28]	Vannata B, Stathis A, Zucca E. Management of the marginal zone lymphomas[J]. Cancer Treat Res, 2015, 165: 227-49. doi: 10.1007/978-3-319-13150-4
[29]	Tobinai K, Klein C, Oya N, et al. A review of obinutuzumab (GA101), a novel type II Anti-CD20 monoclonal antibody, for the treatment of patients with B-Cell malignancies[J]. Adv Ther, 2017, 34(2): 324-56. doi: 10.1007/s12325-016-0451-1
[30]	Noy A, de Vos S, Thieblemont C, et al. Targeting bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma[J]. Blood, 2017, 129(16): 2224-32. doi: 10.1182/blood-2016-10-747345
[31]	Conconi A, Martinelli G, Lopez-Guillermo A, et al. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)[J]. Ann Oncol, 2011, 22(3): 689-95. doi: 10.1093/annonc/mdq416
[32]	Kiesewetter B, Willenbacher E, Willenbacher W, et al. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma[J]. Blood, 2017, 129(3): 383-5. doi: 10.1182/blood-2016-06-720599
[33]	Nastoupil L, Lunning MA, Vose JM, et al. Chemo-free triplet combination of TGR-1202, Ublituximab, and Ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL[J]. Hematol Oncol, 2017, 102(2): 312-23.
[34]	Nakamura S, Sugiyama T, Matsumoto TA, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan[J]. Gut, 2012, 61(4): 507-13. doi: 10.1136/gutjnl-2011-300495
[35]	Ye H, Liu H, Raderer M, et al. High incidence of t(11;18)(q21;q21)in Helicobacterpylori-negative gastric MALT lymphoma[J]. Blood, 2003, 101(7): 2547-50. doi: 10.1182/blood-2002-10-3167
[36]	Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy[J]. Lancet, 2001, 357(9249): 39-40. doi: 10.1016/S0140-6736(00)03571-6
[37]	Wündisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication[J]. J Clin Oncol, 2005, 23(31): 8018-24. doi: 10.1200/JCO.2005.02.3903
[38]	Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin's lymphomas[J]. Hematol Oncol, 2005, 23(1): 10-7.
[39]	王建祥. 血液病诊疗规范[M]. 北京: 中国协和医科大学出版社, 2014.
[40]	Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group[J]. Int J Radiat Oncol Biol Phys, 2015, 92(1): 11-31. doi: 10.1016/j.ijrobp.2015.01.009
[41]	Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as First-Line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial[J]. J Clin Oncol, 2012, 30(24): 2988-94. doi: 10.1200/JCO.2011.41.4466
[42]	Thieblemont C, Molina T, Davi F. Optimizing therapy for nodal marginal zone lymphoma[J]. Blood, 2016, 127(17): 2064-71. doi: 10.1182/blood-2015-12-624296
[43]	Makarova O, Oschlies I, Müller S, et al. Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma[J]. Br J Haematol, 2018, 182(5): 735-9. doi: 10.1111/bjh.14868